Standing Committee for Clinical Affairs
Recommendations
 

It is the objective of EULAR to promote task forces aimed at elaborating recommendations in the field of rheumatology. Such recommendations should follow the published EULAR Standardized Operating Procedures: 
 

Dougados M, Betteridge N, Burmester GR, Euller-Ziegler L, Guillemin F, Hirvonen J, Lloyd J, Ozen S, Da Silva JA, Emery P, Kalden JR, Kvien T, Matucci-Cerinic M, Smolen J; EULAR.

EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees.

Ann Rheum Dis. 2004 Sep; 63(9):1172-6

 

Read more >>

 

These recommendations can be split into three different categories:

  • Recommendations for management of a specific musculoskeletal condition
  • Recommendations for conducting clinical trials in a specific musculoskeletal condition
  • Recommendations for considering the diagnosis of a specific musculoskeletal condition.
 
Recommendations for management

Recommendations for the Reporting of long-term clinical trial extension data

Convenor: Maya Buch

EULAR/ERA recommendations for the management of lupus nephritis and update of the EULAR 2007 SLE guidelines

Convenor: Dimitrios Boumpas

EUSTAR MEDS database

Convenor: Ulf Müller-Ladner 

Strategy meeting on post-EULAR cardiovascular risk management guidelines

Convenor: Micahel Nurmohamed

Recommendations on the management of medium and high dosages of systemic glucocorticoids therapy in rheumatic diseases including patients' perspective

Convenor: Hans Bijlsma

Recommendations for the management of psoriatic arthritis

Convenor: Josef Smolen, Laure Gossec

Recommendations for prevention and management of osteoporotic fractures

Convenor: Willem Lems 

Recommendations for the prevention and treatment of osteoporosis associated with inflammatory musculoskeletal conditions

Convenor: Anthony Woolf 

Points to consider for the use of imaging of peripheral joints in RA clinical practice

Convenor: Phil Conaghan/Mikkel Ostergaard

 
Recommendations for conducting clinical trials

Points to consider in the design of clinical trials in systemic sclerosis

Convenor: Daniel Furst